EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells

Laura Volta iD, Renier Myburgh, Christian Pellegrino iD, Christian Koch iD, Monique Maurer, Francesco Manfredi, Mara Hofstetter, Anne Kaiser, Florin Schneiter iD, Jan Müller, Marco M Buehler iD, Roberto De Luca iD und 5 weitere

Leukemia · 2024-12 · 38 (12) · 2598-2613

DOI: 10.1038/s41375-024-02409-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, online erschienen am 18.09.2024. Verfasst von Laura Volta und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation), Krebsliga Schweiz (Ligue Suisse Contre le Cancer), Universität Zürich (University of Zurich).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAR T-cell products targeting lineage-specific cell-of-origin antigens, thereby eliminating both tumor and healthy counterpart cells, are currently clinically approved therapeutics in B- and plasma-cell malignancies. While they represent a major clinical improvement, they are still limited in terms of efficacy by e.g. single, sometimes low-expressed antigen targeting, and in terms of safety by e.g., lack of on-off activity. Successful cell-of-origin non-discriminative targeting of heterogeneous hematopoietic stem and progenitor cell malignancies, such as acute myeloid leukemia (AML), will require antigen-versatile targeting and off-switching of effectors in order to then allow rescue by hematopoietic stem cell transplantation (HSCT), preventing permanent myeloablation. To address this, we developed adaptor-CAR (AdFITC-CAR) T-cells targeting fluoresceinated AML antigen-binding diabody adaptors. This platform enables the use of adaptors matching the AML-antigen-expression profile and conditional activity modulation. Combining adaptors significantly improved lysis of AML cells in vitro. In therapeutic xenogeneic mouse models, AdFITC-CAR T-cells co-administered with single diabody adaptors were as efficient as direct CAR T-cells, and combinatorial use of adaptors further enhanced therapeutic efficacy against both, cell lines and primary AML. Collectively, this study provides proof-of-concept that AdFITC-CAR T-cells and combinations of adaptors can efficiently enhance immune-targeting of AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsMiceT-LymphocytesXenograft Model Antitumor AssaysMice, Inbred NOD

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
  • Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Philochem AG, Otelfingen, Switzerland.
  • Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland.

ORCID-Profile: Laura Volta, Christian Pellegrino, Christian Koch, Florin Schneiter, Marco M Buehler, Roberto De Luca, Chiara F Magnani, Markus G Manz

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
  • Krebsliga Schweiz (Ligue Suisse Contre le Cancer)
  • Universität Zürich (University of Zurich)
  • Deutsche Krebshilfe (German Cancer Aid)
  • EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
  • ETH Lymphoma Challenge Grant
  • Dr. Horst Böhlke Foundation

Zitieren

APA

Volta, L., Myburgh, R., Pellegrino, C., Koch, C., Maurer, M., Manfredi, F., Hofstetter, M., Kaiser, A., Schneiter, F., Müller, J., Buehler, M. M., De Luca, R., Favalli, N., Magnani, C. F., Schroeder, T., Neri, D., & Manz, M. G. (2024). Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells. Leukemia, 38(12), 2598-2613. https://doi.org/10.1038/s41375-024-02409-1

Vancouver

Volta L, Myburgh R, Pellegrino C, Koch C, Maurer M, Manfredi F, et al. Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells. Leukemia. 2024;38(12):2598-2613. doi:10.1038/s41375-024-02409-1

BibTeX
@article{Volta2024,
  author = {Volta, Laura and Myburgh, Renier and Pellegrino, Christian and Koch, Christian and Maurer, Monique and Manfredi, Francesco and Hofstetter, Mara and Kaiser, Anne and Schneiter, Florin and Müller, Jan and Buehler, Marco M and De Luca, Roberto and Favalli, Nicholas and Magnani, Chiara F and Schroeder, Timm and Neri, Dario and Manz, Markus G},
  title = {Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells},
  journal = {Leukemia},
  year = {2024},
  volume = {38},
  number = {12},
  pages = {2598--2613},
  doi = {10.1038/s41375-024-02409-1}
}
Kostenlos starten →